StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen xGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
352
Period ended Jun 30, 2026
Change on a year earlier
-33.8%
532 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedXGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026352-33.8%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026411-27.4%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025447-20.3%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025539-0.4%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025532-5.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025566+0.9%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024561+6.5%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024541+4.2%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024562+6.0%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024561+4.7%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023527+8.9%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023519+4.8%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023530-0.6%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023536+6.8%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022484-11.2%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022495-4.3%Form 10-Q (filed 2023-10-31) ↗

Breakdown

What makes up xgeva (denosumab — oncology bone metastases & giant cell tumor) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_xgeva_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.